Who is sponsoring NCT00212654?

NCT00212654 is sponsored by Ono Pharmaceutical Co., Ltd..

What drugs are being tested in NCT00212654?

Interventions in NCT00212654: ONO-1101.

What condition does NCT00212654 study?

NCT00212654 studies Postoperative Supraventricular Tachyarrythmia.

Is NCT00212654 still recruiting?

NCT00212654 is currently completed. Last updated 10 October 2012.

Last reviewed 2012-10-10 · How we verify

NCT00212654

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Controlled Study of ONO-1101 in Patients With Postoperative Tachyarrhythmias in Japan

Completed Phase 2/Phase 3 Last updated 10 October 2012

What this trial tests

Phase 2/Phase 3 trial testing ONO-1101 in Postoperative Supraventricular Tachyarrythmia in 165 participants. Completed.

Timeline

1 June 2001

Primary endpoint
1 April 2006

Quick facts

Lead sponsor	Ono Pharmaceutical Co., Ltd.
Phase	Phase 2/Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	165
Start date	1 June 2001
Primary completion	1 April 2006

Drugs / interventions tested

ONO-1101 — full drug profile →

Conditions studied

Postoperative Supraventricular Tachyarrythmia — all drugs for Postoperative Supraventricular Tachyarrythmia →

Sponsor

Ono Pharmaceutical Co., Ltd.

Who can join

Adults 21 to 84, any sex, with Postoperative Supraventricular Tachyarrythmia. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Percentage of patients who met the heart rate reduction criteria (20% reduction from the baseline heart rate and a heart rate of <100 beats/min)

Sponsor's own description

The purpose of this study is to evaluate the efficacy and safety of ONO-1101 in postoperative supraventricular tachyarrhythmias.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Ono Pharmaceutical Co., Ltd. trials

Trials by the same sponsor.

NCT07169708 — A Retrospective Observational Study of Nivolumab in Combination With Chemotherapy as Neoadjuvant Therapy for Resectable · not yet recruiting
NCT06936943 — ONO-4538 Study in Patients With Richter's Transformation · Phase 2 · recruiting
NCT06948448 — A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 an · Phase 2 · recruiting
NCT07198087 — A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impa · Phase 1 · active not recruiting
NCT06803823 — A Study of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease Dementia · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00212654 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ono Pharmaceutical Co., Ltd.
Last refreshed: 10 October 2012

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00212654.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing